0
Skip to Content
Nordic Migraine Symposium 2026
Home
Agenda
Venue & Accommodation
NMS 2025
NMS 2024
NMS 2023
NMS 2022
NMS 2021
NMS 2020
NMS 2019
Contact
REGISTER NOW
Nordic Migraine Symposium 2026
Home
Agenda
Venue & Accommodation
NMS 2025
NMS 2024
NMS 2023
NMS 2022
NMS 2021
NMS 2020
NMS 2019
Contact
REGISTER NOW
Home
Agenda
Venue & Accommodation
Folder: Previous years
Back
NMS 2025
NMS 2024
NMS 2023
NMS 2022
NMS 2021
NMS 2020
NMS 2019
Contact
REGISTER NOW

Safety, tolerability and possible interactions of the MAbs

Session 5: a-CGRP registries and RWE

Ville Artto

Department of Neurology, Helsinki University Central Hospital

Previous

Multidisciplinary management

Next

Rationale for switching of preventative treatments

You Might Also Like

Related Embedded Video Item Thumbnail New EHF guideline on the use of MAb’s for migraine prevention
Related Embedded Video Item Thumbnail Multidisciplinary management
Related Embedded Video Item Thumbnail Migraine in pediatric
Related Embedded Video Item Thumbnail Comorbidities and management
Related Embedded Video Item Thumbnail Biomarkers with focus on genetics

Privacy policy

Teva Privacy Notice |Teva Pharmaceuticals

Legal Notes | Teva Pharmaceuticals

Accessibility Statement

Teva code of conduct


Norway, Finland, Denmark: AJO-DK-NP-00128